160998-59-4 Usage
Description
5-Chloromethyl-2-(triphenylmethyl)-2H-tetrazole is an organic compound characterized by its tetrazole ring and triphenylmethyl group. It is a versatile building block in the synthesis of various chemical compounds and has potential applications in the pharmaceutical and chemical industries due to its unique structure and reactivity.
Uses
Used in Pharmaceutical Industry:
5-Chloromethyl-2-(triphenylmethyl)-2H-tetrazole is used as a reactant for the preparation of carbazole derivatives, which serve as selective β3 adrenergic agonists. These agonists have potential applications in the treatment of various medical conditions, such as obesity and type 2 diabetes, by modulating the activity of β3 adrenergic receptors.
Used in Chemical Synthesis:
In the chemical industry, 5-chloromethyl-2-(triphenylmethyl)-2H-tetrazole can be utilized as a key intermediate in the synthesis of a wide range of compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals. Its unique structure and reactivity make it a valuable building block for the development of new molecules with diverse applications.
Check Digit Verification of cas no
The CAS Registry Mumber 160998-59-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,0,9,9 and 8 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 160998-59:
(8*1)+(7*6)+(6*0)+(5*9)+(4*9)+(3*8)+(2*5)+(1*9)=174
174 % 10 = 4
So 160998-59-4 is a valid CAS Registry Number.
160998-59-4Relevant articles and documents
Carbazolyl-substituted ethanolamines as selective beta -3 agonists
-
, (2008/06/13)
PCT No. PCT/US97/15230 Sec. 371 Date May 4, 1998 Sec. 102(e) Date May 4, 1998 PCT Filed Aug. 28, 1997 PCT Pub. No. WO98/09625 PCT Pub. Date Mar. 12, 1998Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.
SELECTIVE BETA 3 ADRENERGIC AGONISTS
-
, (2008/06/13)
The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II: STR1
